ClinicalTrials.gg
CompletedNCT06047184Updated Aug 18, 2026

Phase I Study of BEBT-209 in Women With Advanced Breast Cancer

A Phase 1 interventional study of BEBT-209 capsules and Letrozole tablets in Advanced Breast Cancer, sponsored by BeBetter Med Inc. Completed at 2 sites in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by BeBetter Med Inc · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 1 month after the study started (first participant enrolled Jul 2019, registered Sep 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,928 studies in Breast Neoplasms with a site in China — 866 open to participants now, 1,064 under way, 210 of them phase 3. Breast Neoplasms · China.

Enrollment
834th of 1,519
100 · median 120
Started
2019
with 113 others
Phase 1
171 of 1,928
61 open now
Registered
1,176th of 1,928
by date

Among the 1,928 studies in Breast Neoplasms with a site in China, this one is the 834th largest by enrollment of the 1,519 interventional ones that give a count, is one of 114 that started in 2019, is one of 171 in phase 1, and was the 1,176th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

866 of the 1,928 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

861 more — sign in →

All 866 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,928 studies in Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

This clinical study includes a dose escalation trial of BEBT-209 monotherapy in HR +/HER2- advanced breast cancer patients and a Phase 1b trial of BEBT-209 as a single therapy, in combination with letrozole, and in combination with fulvestrant in ER +/HER2- advanced breast cancer in women. To evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BEBT-209 as a single therapy, in combination with letrozole, and in combination with fulvestrant. To determine the recommended dose for late clinical studies of monotherapy or combination therapy in patients with HR +/HER2- advanced breast cancer.

Read the detailed description
  • Dose escalation phase: To conduct approximately 6 dose levels, with a starting dose of 25 mg/day of BEBT-209, and subsequent dose groups were first dose escalated at 100%, with dose escalation at 50% for subsequent dose groups if one drug-related Grade 2 nonhematologic or Grade 3 hematologic toxicity was identified and dose-limiting toxicity was not reached. If one dose limiting toxicity was identified and the maximum tolerated dose was not reached, dose escalation was performed at 33% for the subsequent dose groups.
  • Phase Ib of BEBT-209 as single therapy, in Combination with Letrozole, in Combination with Fulvestrant: According to the pharmacokinetics, safety and preliminary efficacy of BEBT-209 in the dose escalation phase, one dose was selected for the BEBT-209 monotherapy group, two doses were selected for the combination with letrozole group, and two doses were selected for the combination with fulvestrant group, and all five groups were continuously administered until disease progression or unacceptable toxicity or patient withdrawal or death. Late phase clinical trials were conducted as appropriate based on preliminary safety tolerability, pharmacokinetics, and preliminary efficacy results from Phase 1b.

Participants will need to understand the requirements and risks of the trial, sign an informed consent form, accept the dosing regimen required by the trial protocol, and follow the investigator's guidance.

03

Conditions studied

  • Advanced Breast Cancer

Browse trials for

Keywords

  • BEBT-209
  • Safety
  • Tolerability
  • Pharmacokinetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: ≥18 years old;
  2. Confirmed HR +/- breast cancer in women with evidence of focal recurrence or not amenable to curative surgical resection or radiation therapy.
  3. Menstrual status:

    3.1 Subjects enrolled in the dose escalation phase, Phase Ib combined with letrozole, combined with fulvestrant therapy were required to be female patients who achieved menopausal status or were treated with LHRH agonists; 3.2 Subjects enrolled in Phase Ib monotherapy and combined fulvestrant second-line/third-line therapy are required to be , premenopausal/ perimenopausal, and amenorrheic women;

    Menopausal status(note 2) is defined as having met any of the following:

    • Prior bilateral oophorectomy;
    • Age≥ 60 years old
    • Age \< 60 years, Spontaneous amenorrhea ≥ 12 months and blood follicle-stimulating hormone (FSH) and estradiol (E2) levels within the postmenopausal range (in conjunction with reference ranges at each site) in the absence of chemotherapy, tamoxifen, toremifene, or ovarian castration within the past year;
    • Patients \< 60 years of age who were taking tamoxifen or toremifene had blood follicle-stimulating hormone (FSH) and estradiol (E2) levels within the postmenopausal range on two consecutive occasions (in conjunction with reference ranges at each site);
    • Not meeting the above criteria for menopause is considered premenopausal or perimenopausal; Note 2:Premenopausal/perimenopausal female patients agree to use concomitant luteinizing hormone-releasing hormone (LHRH agonist) and start treatment with LHRH agonist at least 28 ± 2 days before the start of the first dose of study drug can be considered to meet inclusion criteria 3.1 (if LHRH agonist has been used for ≥ 21 days but \< 26 days before the first dose, hormone levels are eligible can be considered to meet inclusion criteria 3.1) ;
  4. Prior Therapy( Note 3):

    4.1 Patients who have failed standard therapy or for whom standard therapy is not applicable are required for the dose escalation phase; 4.2 Phase IB monotherapy group: patients who have previously failed antiestrogen therapy and received at least 1 chemotherapy regimen; 4.3 The stage IB combined letrozole group required no previous first-line treatment for focal recurrent or metastatic ER + breast cancer; 4.4 Prior therapy in the Stage IB combined fulvestrant arm must have met one of the following: 4.4.1 Premenopausal/perimenopausal/postmenopausal patients can be enrolled, and premenopausal/perimenopausal patients are required to use luteinizing hormone-releasing hormone (LHRH agonist) at the same time; 4.4.2 Progression confirmed by imaging during or within 12 months after discontinuation of endocrine therapy (AI or TAM); 4.4.3 Progression confirmed by imaging during or within one month after discontinuation of endocrine therapy for the first recurrence and metastasis; 4.4.4 Patients in the relapse or metastatic stage are allowed to receive no more than one line of chemotherapy in addition to endocrine therapy.

    Note 3: The number of lines of therapy and corresponding menstrual status definitions refer to the Ribociclib Phase 3 Clinical Study (NCT02422615), the abemaciclib Phase 2 Clinical Study (Clin Cancer Res. 2017 September 01; 23 (17): 5218 - 5224), and the Palbociclib in Combination with Fulvestrant Clinical Study (NCT02738866).

  5. as defined by V.1.1 or osteolytic bone metastases only as judged by the investigator based on clinical presentation. Tumor lesions previously treated with radiotherapy or other local therapy were considered measurable only if disease progression at the treatment site was clearly documented after completion of treatment.
  6. score of 0-2.
  7. Have adequate organ and bone marrow function, defined as follows: ≥1,500/mm\^3(1.5 x 10\^9 /L); ≥ 100,000/mm\^3 (100 x10

    \^9 /L); ≥ 9 g/dL (90 g/L); Both or AST ≤ 2.5×, and ALT or AST ≤ 5.0×ULN in liver metastasis; Total (TBIL) ≤ 1.5×ULN, 3.0×≤ULN in liver metastasis; Serum creatinine ≤ 1.5 x ULN or estimated ≥ 60 mL/min (according to the Cockcroft and Gault formula).

  8. Resolution of all acute toxicities from prior anticancer therapy or surgical procedures to baseline severity or NCICTCAE version 5.0 ≤ Grade 1 (except alopecia or other toxicities that, in the opinion of the investigator, pose no safety risk to the patient).
  9. Female subjects of must have a negative serum pregnancy test within 7 days prior to starting study drug and be willing to use a medically recognized highly effective form of (eg, intrauterine device, contraceptive pill, or condom) during the study and for 1 month after the last dose of study drug.
  10. Willing to sign the form after thorough understanding.

Exclusion criteria

Exclusion Criteria:

  1. combined with any other (except adequately treated basal cell or squamous cell skin cancer or cervical carcinoma in situ).
  2. symptomatic, advanced patients who have disseminated to the viscera and are at risk of life-threatening complications in the short term (patients with visceral crisis); inflammatory breast cancer.
  3. Known or symptomatic active characterized by clinical symptoms, cerebral edema, spinal cord compression, carcinomatous meningitis, , and/or progressive growth.
  4. Major surgery, chemotherapy, radiation therapy, any agent, or other anticancer therapy within 4 weeks prior to the first dose.
  5. Patients who have received the following treatments within 7 days prior to study entry: drugs known to be potent inhibitors/inducers of ; drugs known to significantly prolong the .
  6. previous treatment with CDK4/6 inhibitors.
  7. Patients previously treated with fulvestrant and everolimus cannot be enrolled in cohorts 4 and 5.
  8. QTc interval > 480 msec (based on the average of three screening [ECGs]); a history or confirmed family history of long QT syndrome; a history of ventricular arrhythmias, or current use of antiarrhythmic drugs or a defibrillator device implanted to treat ventricular arrhythmias.
  9. Uncontrolled electrolyte disturbances that may affect the effects of QTc prolonging drugs.
  10. previous myocardial infarction, severe/unstable angina pectoris, NCICTCAE version 5.0 grade ≥ 2 sustained arrhythmia, atrial fibrillation of any grade, coronary/peripheral artery bypass grafting, symptomatic congestive heart failure, cerebrovascular accident (including or symptomatic pulmonary embolism);
  11. active inflammatory bowel disease or chronic diarrhea, short bowel syndrome, or any upper gastrointestinal surgery including gastrectomy; known malabsorption syndrome or other conditions that may impair absorption of BEBT-209.
  12. Known history of or suspected symptoms of hypersensitivity to any component of letrozole, fulvestrant, BEBT-209 capsules.
  13. Clinically significant active infections including (HBV), (HCV), known (HIV), or acquired immunodeficiency syndrome (AIDS) -related diseases. Active hepatitis B was defined as having positive hepatitis B surface antigen (HBsAg) or hepatitis B e antigen (HBeAg) and HBV DNA ≥ 2000 IU/ml (equivalent to 104 copies/ml); active hepatitis C was defined as having HCV RNA above the lower limit of detection.
  14. Other serious acute or chronic medical or psychiatric conditions or laboratory abnormalities that may increase the risk of study participation or increase the risk associated with study drug administration, or interfere with study results, as well as other conditions that, in the opinion of the investigator, would make the patient inappropriate for participation in this study.
  15. Recent active suicidal ideation or behavior.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Monotherapy group 1

    BEBT-209 capsules, 25mg once daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.

    Drug: BEBT-209 capsules

  • Experimental
    Monotherapy group 2

    BEBT-209 capsules, 25mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.

    Drug: BEBT-209 capsules

  • Experimental
    Monotherapy group 3

    BEBT-209 capsules, 50mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.

    Drug: BEBT-209 capsules

  • Experimental
    Monotherapy group 4

    BEBT-209 capsules, 75mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.

    Drug: BEBT-209 capsules

  • Experimental
    Monotherapy group 5

    BEBT-209 capsules, 100mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.

    Drug: BEBT-209 capsules

  • Experimental
    Monotherapy group 6

    BEBT-209 capsules, 150mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.

    Drug: BEBT-209 capsules

  • Experimental
    BEBT-209 combined with the letrozole group 1

    BEBT-209 capsules, 100mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle. Letrozole tablets, 2.5mg each time, once a day for 4 weeks, 4 weeks as a treatment cycle.

    Drug: BEBT-209 capsules · Drug: Letrozole tablets

  • Experimental
    BEBT-209 combined with the letrozole group 2

    BEBT-209 capsules, 75mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle. Letrozole tablets, 2.5mg each time, once a day for 4 weeks, 4 weeks as a treatment cycle.

    Drug: BEBT-209 capsules · Drug: Letrozole tablets

  • Experimental
    BEBT-209 combined with the Fulvestrant Group 1

    BEBT-209 capsules, 75mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle. Fulvestrant, injection, 500mg each time, 1 time on day 1 and day 15 of the first cycle, and once on the first day of each cycle from the second cycle, 4 weeks as a treatment cycle

    Drug: BEBT-209 capsules · Drug: Fulvestrant

  • Experimental
    BEBT-209 combined with the Fulvestrant Group 2

    BEBT-209 capsules, 100mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle. Fulvestrant, injection, 500mg each time, 1 time on day 1 and day 15 of the first cycle, and once on the first day of each cycle from the second cycle, 4 weeks as a treatment cycle

    Drug: BEBT-209 capsules · Drug: Fulvestrant

Interventions

  • BEBT-209 capsules, 25mg once daily, or 25mg, 50mg, 75mg, 100mg, 150mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.

    Also known as: KCBT-0191

  • Letrozole tablets, 2.5mg each time, once a day for 4 weeks, 4 weeks as a treatment cycle.

    Also known as: Femara

  • Fulvestrant, injection, 500mg each time, 1 time on day 1 and day 15 of the first cycle, and once on the first day of each cycle from the second cycle, 4 weeks as a treatment cycle

    Also known as: FASLODEX

06

What researchers measure

Primary outcomes

  1. MTD

    Maximum tolerated dose

    Time frame: 4 weeks

  2. DLT

    Dose-limiting toxicity

    Time frame: 4 weeks

Secondary outcomes

  1. ORR

    Objective response rate

    Time frame: From date of administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months

  2. CBR

    clinical benefit rate

    Time frame: From date of administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months

  3. PFS

    progression-free survival

    Time frame: From date of administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months

  4. DOR

    Duration of response

    Time frame: From date of administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months

  5. Cmax

    Peak Plasma Concentration

    Time frame: Day 1 and Day 21 of cycle 1 before and within 48 hours after administration (each cycle is 28 days)

  6. Tmax

    Time of peak Plasma Concentration

    Time frame: Day 1 and Day 21 of cycle 1 before and within 48 hours after administration (each cycle is 28 days)

  7. t1/2

    Half-life of plasma drug concentrations

    Time frame: Day 1 and Day 21 of cycle 1 before and within 48 hours after administration (each cycle is 28 days)

  8. AUC0-48h

    Area under the blood concentration time curve from 0 to 48 hours after administration

    Time frame: Day 1 and Day 21 of cycle 1 before and within 48 hours after administration (each cycle is 28 days)

  9. AUC0-last

    Area under the blood concentration time curve from time zero to the last dose

    Time frame: Day 1 and Day 21 of cycle 1 before and within 48 hours after administration (each cycle is 28 days)

  10. CL/F

    Apparent total plasma clearance

    Time frame: Day 1 and Day 21 of cycle 1 before and within 48 hours after administration (each cycle is 28 days)

  11. Vd

    Apparent volume of distribution

    Time frame: Day 1 and Day 21 of cycle 1 before and within 48 hours after administration (each cycle is 28 days)

07

Study locations

2 sites
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
  • Xiangya Hospital Central South University
    Changsha, Hunan 410013, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Jan 2024, 54 months.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 54 months is above that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2023
First posted
Sep 21, 2023
StartActual
Jul 15, 2019
Primary completionActual
Jan 30, 2024
CompletionActual
Jan 30, 2024
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06047184
Lead sponsor
BeBetter Med Inc
Collaborators
Hunan Cancer Hospital, Xiangya Hospital of Central South University
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Jul 15, 2019
Primary completion
Jan 30, 2024
Completion
Jan 30, 2024
Last update
Aug 18, 2026

Study contacts

Quchang Ouyang, Phd
principal investigator · Hunan Cancer Hospital
Shouman Wang, Phd
principal investigator · Xiangya Hospital of Central South University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BEBT-209

Start the discussion